---
title: "🏊‍♀️ Dive into the CHRYSALIS study: enhancing EGFR ex20 insertion-mutated NSCLC treatment"
---

Explore the latest in EGFR lung cancer research through our CHRYSALIS resources 📖

| View in browser Weekly newsletter  9th November 2023      Editor's pick Publication In Focus: CHRYSALIS study Patients with EGFR exon 20 insertion mutations are difficult to treat or do not experience treatment response with commonly used therapies that target EGFR. How is amivantamab reshaping the landscape of lung cancer therapy? Find out in our latest In Focus feature. Latest articles Symposium on Primary Breast Cancer in Older Women The Symposium on Primary Breast Cancer in Older Women (1 March 2024; Nottingham, UK) has an overarching goal of optimizing the management of primary breast cancer in older women. Future Oncology is calling all breast cancer experts to submit their abstract for the next symposium. Find out more here.  🎥 Video: a plain language summary of results from the CHRYSALIS study   EGFR mutations are one of the most common causes of NSCLC tumors. Preliminary data from the CHRYSALIS study suggests that amivantamab may hold promise for these patients. Explore the latest in EGFR lung cancer research with our video summary of this study.    3D-printed tumor model enhances researchers understanding of heterogeneous tumors   An interdisciplinary team of researchers have created a method to produce more accurate 3D models of complex tumors, enabling researchers to test different therapeutic strategies in greater detail than before. Find out more from this news piece published on our sister site BioTechniques.  Topics: Cancer biology and pathology \| Clinical trials \| Drug approvals \| Drug development \| Diagnostics \| Epidemiology \| Genetics and genomics \| Immuno- oncology \| Industry and business \| Patient perspective \| Personalized medicine \| Preclinical research and trials \| Prevention and screening \| Targeted therapies \| Future Science Ltd, Unitec House, 2 Albert Place, Finchley Central, London N3 1QB, UK, +44 (0) 20 8371 6090 Manage preferences Privacy Policy \| Terms & Conditions |
| --- |